A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Two Patient Groups with Acromegaly and Neuroendocrine Tumours (NET) Previously Treated with Sandostatin(R) LAR(R)

Trial Profile

A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Two Patient Groups with Acromegaly and Neuroendocrine Tumours (NET) Previously Treated with Sandostatin(R) LAR(R)

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Octreotide (Primary)
  • Indications Acromegaly; Neuroendocrine tumours
  • Focus Pharmacokinetics
  • Sponsors Camurus
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
    • 12 Jul 2016 According to a Camurus media release, status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top